Correlation of the expression of human kallikrein-related peptidases 4 and 7 with the prognosis in oral squamous cell carcinoma

Head and Neck

Volumn 33, Issue 4, 2011, Pages 566-572

  Zhao, Hong ^a,b   Dong, Ying ^c   Quan, Jingjing ^a   Smith, Robert ^a   Lam, Alfred ^a   Weinstein, Stephen ^d   Clements, Judith ^c   Johnson, Newell W ^a   Gao, Jin ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^d GOLD COAST UNIVERSITY HOSPITAL   (Australia)

Author keywords

immunohistochemistry; kallikrein serine proteases; oral squamous cell carcinoma; prognosis

Indexed keywords

KALLIKREIN;

ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; MOUTH CANCER; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KALLIKREINS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 79952923204     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21496     Document Type: Article

References (31)

1. Warnakulasuriya S,. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 2009; 45: 309-316.
2. Johnson N,. Global epidemiology of oral cancer. In:, Shah J, Johnson N, Batsakis J, Dunitz M, Oral Cancer. New York: Thieme Medical; 2003. pp 3-32.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
4. Levental KR, Yu H, Kass L, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009; 139: 891-906.
5. Shibue T, Weinberg RA,. Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc Natl Acad Sci U S A 2009; 106: 10290-10295.
6. Pettus JR, Johnson JJ, Shi Z, et al. Multiple kallikrein (KLK 5, 7, 8, and 10) expression in squamous cell carcinoma of the oral cavity. Histol Histopathol 2009; 24: 197-207.
7. Yousef GM, Diamandis EP,. Tissue kallikreins: new players in normal and abnormal cell growth? Thromb Haemost 2003; 90: 7-16. (Pubitemid 36873853)
8. Lawrence MG, Lai J, Clements JA,. Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus. Endocr Rev 2010. [Epub ahead of print].
9. Debela M, Beaufort N, Magdolen V, et al. Structures and specificity of the human kallikrein-related peptidases KLK 4, 5, 6, and 7. Biol Chem 2008; 389: 623-632. (Pubitemid 352009408)
10. Paliouras M, Borgono C, Diamandis EP,. Human tissue kallikreins: the cancer biomarker family. Cancer Lett 2007; 249: 61-79. (Pubitemid 46427999)
11. Xi Z, Klokk TI, Korkmaz K, et al. Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer. Cancer Res 2004; 64: 2365-2370. (Pubitemid 38523888)
12. Obiezu CV, Scorilas A, Katsaros D, et al. Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients. Clin Cancer Res 2001; 7: 2380-2386. (Pubitemid 32751639)
13. Dong Y, Kaushal A, Bui L, et al. Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas. Clin Cancer Res 2001; 7: 2363-2371. (Pubitemid 32751637)
14. Gao J, Collard RL, Bui L, Herington AC, Nicol DL, Clements JA,. Kallikrein 4 is a potential mediator of cellular interactions between cancer cells and osteoblasts in metastatic prostate cancer. Prostate 2007; 67: 348-360. (Pubitemid 46341076)
15. Hu JC, Zhang C, Sun X, et al. Characterization of the mouse and human PRSS17 genes, their relationship to other serine proteases, and the expression of PRSS17 in developing mouse incisors. Gene 2000; 251: 1-8. (Pubitemid 30339411)
16. Simon M, Jonca N, Guerrin M, et al. Refined characterization of corneodesmosin proteolysis during terminal differentiation of human epidermis and its relationship to desquamation. J Biol Chem 2001; 276: 20292-20299.
17. Debela M, Hess P, Magdolen V, et al. Chymotryptic specificity determinants in the 1.0 A structure of the zinc-inhibited human tissue kallikrein 7. Proc Natl Acad Sci U S A 2007; 104: 16086-16091. (Pubitemid 350099368)
18. Komatsu N, Takata M, Otsuki N, et al. Expression and localization of tissue kallikrein mRNAs in human epidermis and appendages. J Invest Dermatol 2003; 121: 542-549. (Pubitemid 37072266)
19. Caubet C, Jonca N, Brattsand M, et al. Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7. J Invest Dermatol 2004; 122: 1235-1244. (Pubitemid 38651099)
20. Prezas P, Scorilas A, Yfanti C, et al. The role of human tissue kallikreins 7 and 8 in intracranial malignancies. Biol Chem 2006; 387: 1607-1612. (Pubitemid 44837586)
21. Dong Y, Kaushal A, Brattsand M, Nicklin J, Clements JA,. Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers. Clin Cancer Res 2003; 9: 1710-1720. (Pubitemid 36554595)
22. Prezas P, Arlt MJ, Viktorov P, et al. Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells. Biol Chem 2006; 387: 807-811. (Pubitemid 43964805)
23. Kyriakopoulou LG, Yousef GM, Scorilas A, et al. Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer. Clin Biochem 2003; 36: 135-143. (Pubitemid 36287493)
24. Choi S, Myers JN,. Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. J Dent Res 2008; 87: 14-32.
25. Hart PS, Hart TC, Michalec MD, et al. Mutation in kallikrein 4 causes autosomal recessive hypomaturation amelogenesis imperfecta. J Med Genet 2004; 41: 545-549. (Pubitemid 38932116)
26. Johnson SK, Ramani VC, Hennings L, Haun RS,. Kallikrein 7 enhances pancreatic cancer cell invasion by shedding E-cadherin. Cancer 2007; 109: 1811-1820. (Pubitemid 46668545)
27. Ramani VC, Haun RS,. Expression of kallikrein 7 diminishes pancreatic cancer cell adhesion to vitronectin and enhances urokinase-type plasminogen activator receptor shedding. Pancreas 2008; 37: 399-404.
28. Veveris-Lowe TL, Lawrence MG, Collard RL, et al. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. Endocr Relat Cancer 2005; 12: 631-643. (Pubitemid 41482997)
29. Klucky B, Mueller R, Vogt I, et al. Kallikrein 6 induces E-cadherin shedding and promotes cell proliferation, migration, and invasion. Cancer Res 2007; 67: 8198-8206. (Pubitemid 47395156)
30. Santin AD, Cane S, Bellone S, et al. The serine protease stratum corneum chymotryptic enzyme (kallikrein 7) is highly overexpressed in squamous cervical cancer cells. Gynecol Oncol 2004; 94: 283-288. (Pubitemid 39024528)
31. Dong Y, Tan OL, Loessner D, et al. Kallikrein-related peptidase 7 promotes multicellular aggregation via the alph(5)beta(1) integrin pathway and paclitaxel chemoresistance in serous epithelial ovarian carcinoma. Cancer Res 2010; 70: 2624-2633.